" A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer" |
Completed |
LEE011 (Ribociclib) |
3 |
CLEE011E2301 |
KKUH , KFSH & RC-R , NGHA-R , NGHA-J |
Multicenter, open-label, study to evaluate safety,tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in pediatric patients from1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction) |
Completed |
Entresto |
3 |
CLCZ696B2319 |
KFSH&RC-R , KFSH-D |
A Retrospective Observational Non-Interventional Study (NIS) to assess Patient Characteristics and Healthcare Resource Use (HCRU) among COVID-19 Patients Receiving Treatment with Nirmatrelvir; Ritonavir (PAXLOVIDTM) in the Kingdom of Saudi Arabia (KSA) |
Ongoing |
Paxlovid |
4 |
C4671054 |
King Faisal Specialist Hospital and Research Center (Riyadh) , King Faisal Specialist Hospital and Research Center (Jeddah) , King Abdulaziz Medical City NG (Riyadh) , King Abdulaziz Medical City NG (Riyadh) |
Stroke and High-risk TIAs Outcomes with Reduction of Treatment duration in Emergency Rooms. (SHORTER-Study). |
Ongoing |
PLAVIX Clopidogrel 75 MG TABLET |
3 |
1 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Medical City (Riyadh) |
A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period With Macitentan 75 mg. (UNISUS) |
Ongoing |
Macitentan |
3 |
AC-055-315 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Medical City (Riyadh) |
AN OPEN-LABEL STUDY IN PEDIATRIC (<18 YEARS OF AGE), SEVERE HEMOPHILIA A PARTICIPANTS (COAGULATION FACTOR ACTIVITY <1%) WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY ≤2%) WITH OR WITHOUT INHIBITORS COMPARING 12 MONTHS OF HISTORICAL STANDARD TREATMENT TO MARSTACIMAB PROPHYLAXIS |
Ongoing |
Marstacimab |
3 |
B7841008 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam) |
Non-Interventional Study of the Change in Joint Health in Adult Patients with Haemophilia A after Switching to Prophylaxis with Turoctocog Alfa Pegol (N8-GP) |
Ongoing |
Turoctocog Alfa Pegol (N8-GP) |
4 |
NN7088-492 |
King Abdulaziz University Hospital (Jeddah),King Fahad Hospital (Jeddah) |
The Efficacy and Safety of Degludec Use for Glycemic Control in Critically Ill Patients: A Prospective Interventional Study |
Ongoing |
INSULIN ASPART,INSULIN DEGLUDEC |
3 |
1 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
Assessment of Quality of Life in Patients with Relapsing Multiple Sclerosis treated with Cladribine tablets in the Kingdom of Saudi Arabia |
Ongoing |
Cladribine |
4 |
MS700568-2 |
King Fahad Medical City (Riyadh),King Saud Medical City (Riyadh),King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Medical City NG (Jeddah),King Faisal Specialist Hospital and Research Center (Jeddah),Dallah Hospital (Riyadh) |
Medical treatment for congenital hereditary endothelial dystrophy |
Ongoing |
Nepafenac |
2 |
22071-CT |
King Khaled Eye Specialist Hospital (Riyadh) |